PB
PBN.F Alterity Therapeutics Limited
- Market cap
- EUR 32.1M
- P/E
- -
- P/B
- 1.56x
- ROE
- -54.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is PBN.F undervalued?
Graham numberThe Graham number of Alterity Therapeutics Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Alterity Therapeutics Limited fundamental analysis
No fundamental analysis for Alterity Therapeutics Limited yet.
Alterity Therapeutics Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Alterity Therapeutics Limited
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 tha…
Full company profileAlterity Therapeutics Limited financial statements
Alterity Therapeutics Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 132K | 201K | 109K | 0.00 | -7.58K | -5.20K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.91M | 2.90M | 4.63M | - | - | - | - | - | - | - |
| Operating Income | -6.64M | -7.77M | -12.4M | -13.5M | -14.7M | -15.1M | -14.4M | -19.6M | -12.5M | -25.1M |
| EBITDA | -9.64M | -10.9M | -17.3M | -13.4M | -14.7M | -15.1M | -14.3M | -19.5M | -12.3M | -25.0M |
| Net Income | -7.54M | -8.27M | -12.3M | -13.5M | -15.3M | -12.8M | -13.8M | -19.1M | -12.1M | -23.4M |
| EPS | -0.01 | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.18 | -0.07 | -0.11 |
| Balance Sheet | ||||||||||
| Total Assets | 25.3M | 18.7M | 19.9M | 9.91M | 33.6M | 41.4M | 27.3M | 19.2M | 46.0M | 46.0M |
| Total Liabilities | 1.59M | 2.64M | 3.36M | 2.76M | 3.12M | 5.89M | 4.50M | 5.43M | 3.62M | 3.29M |
| Shareholders' Equity | 23.7M | 16.1M | 16.6M | 7.15M | 30.5M | 35.5M | 22.8M | 13.8M | 42.4M | 42.7M |
| Cash & Short-term Investments | 21.9M | 15.2M | 14.4M | 9.20M | 28.1M | 34.8M | 15.8M | 12.6M | 33.2M | 37.3M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -5.87M | -6.25M | -14.0M | -9.43M | -17.3M | -12.3M | -20.0M | -12.6M | -11.5M | - |
| Capital Expenditure | 27.9K | 62.4K | 7.02K | 16.7K | 10.5K | 89.1K | 7.31K | 5.72K | 0.00 | 0.00 |
| Free Cash Flow | -5.89M | -6.31M | -14.0M | -9.45M | -17.5M | -12.4M | -20.0M | -12.6M | -11.5M | -22.5M |
| Ratios | ||||||||||
| ROE | -31.8% | -51.4% | -74.5% | -188.2% | -50.2% | -36.2% | -60.5% | -138.6% | -28.6% | -54.8% |
| ROA | -29.8% | -44.1% | -62.0% | -135.8% | -45.6% | -31.1% | -50.5% | -99.5% | -26.4% | -50.9% |
| Net Profit Margin | -5,696.6% | -4,108.8% | -11,367.3% | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Alterity Therapeutics Limited dividends
Alterity Therapeutics Limited has not paid dividends in the last 9 fiscal years.
Last stock split: 1:50 on Jun 3, 2026.
Who owns Alterity Therapeutics Limited
- Insiders 8.69%
- Institutions 17.98%
- Public & others 73.33%
- Shares outstanding 229M
- Free float 173M
Alterity Therapeutics Limited company profile
- Company name
- Alterity Therapeutics Limited
- Ticker
- PBN.F
- ISIN
- AU0000043945
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 11
- Fiscal year end
- June
- Address
- 500 Collins Street, Melbourne, VIC, Australia, 3000
- Phone
- 61 3 9349 4906
- Website
- alteritytx.com
About Alterity Therapeutics Limited
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as bioMUSE, biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
Alterity Therapeutics Limited management
5- Dr. David A. Stamler M.D.CEO, MD & Director · born 1961
- Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A.CFO & Company Secretary · born 1982
- Dr. Rudolph Emile Tanzi Ph.D.Chief Scientific Advisor and Member of Research & Development Advisory Board · born 1959
- Dr. Steven D. Targum M.D.Chief Medical Advisor
- Dr. Robert ChernyHead of Research